New Drug JNJ-40411813 Shows No Benefit for Focal Seizures

Source: Epilepsia

Summary

A study was conducted to evaluate the effectiveness and safety of a new medication called JNJ-40411813 when used alongside two existing epilepsy treatments, levetiracetam and brivaracetam. The research involved 110 adults aged 18 to 64 who have focal onset seizures, which are a type of seizure that starts in one area of the brain. The study lasted 12 weeks and was designed to compare the new medication to a placebo, which is an inactive substance that looks like the real drug.

The results showed that JNJ-40411813 did not provide any significant benefits compared to the placebo in reducing the number of seizures or improving other important measures. In both groups of participants, the time it took to return to their baseline seizure count was similar, indicating that the new medication did not help in controlling seizures better than the placebo. While the medication was generally safe and side effects were mild to moderate, it did not show the hoped-for effectiveness.

This study is important because it helps to understand the potential of new treatments for epilepsy, especially for those who do not respond well to current medications. However, since JNJ-40411813 did not demonstrate significant benefits, it is not recommended for use in patients with focal seizures. The study's design was effective in limiting exposure to ineffective treatments, but further research is needed to find better options for managing epilepsy.

Original source